- Home
- PYPD vs IMRN Comparison
PYPD vs IMRN Comparison
Compare PYPD & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- IMRN
- Stock Information
- Founded
- PYPD 2008
- IMRN 1994
- Country
- PYPD Israel
- IMRN Australia
- Employees
- PYPD N/A
- IMRN N/A
- Industry
- PYPD Medical/Dental Instruments
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- IMRN Health Care
- Exchange
- PYPD Nasdaq
- IMRN Nasdaq
- Market Cap
- PYPD 16.3M
- IMRN 15.0M
- IPO Year
- PYPD 2020
- IMRN N/A
- Fundamental
- Price
- PYPD $3.54
- IMRN $2.74
- Analyst Decision
- PYPD Buy
- IMRN Strong Buy
- Analyst Count
- PYPD 2
- IMRN 1
- Target Price
- PYPD $12.00
- IMRN $5.00
- AVG Volume (30 Days)
- PYPD 4.6K
- IMRN 6.0K
- Earning Date
- PYPD 11-06-2024
- IMRN 10-15-2024
- Dividend Yield
- PYPD N/A
- IMRN N/A
- EPS Growth
- PYPD N/A
- IMRN N/A
- EPS
- PYPD N/A
- IMRN N/A
- Revenue
- PYPD N/A
- IMRN $3,271,194.00
- Revenue This Year
- PYPD N/A
- IMRN N/A
- Revenue Next Year
- PYPD N/A
- IMRN N/A
- P/E Ratio
- PYPD N/A
- IMRN N/A
- Revenue Growth
- PYPD N/A
- IMRN 171.67
- 52 Week Low
- PYPD $2.95
- IMRN $1.48
- 52 Week High
- PYPD $9.20
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- PYPD 46.92
- IMRN 55.49
- Support Level
- PYPD $3.31
- IMRN $2.66
- Resistance Level
- PYPD $3.75
- IMRN $2.87
- Average True Range (ATR)
- PYPD 0.19
- IMRN 0.14
- MACD
- PYPD -0.00
- IMRN 0.01
- Stochastic Oscillator
- PYPD 31.16
- IMRN 67.09
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.